Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

Rhea-AI Summary

Selecta Biosciences (NASDAQ: SELB) will host a conference call on March 11, 2020, at 8:30 a.m. ET to discuss its financial results for Q4 and full-year 2020 along with operational highlights. The company leverages its ImmTOR™ platform to develop therapies aimed at mitigating unwanted immune responses. Notably, it plans to enter clinical trials for its AAV gene therapies aimed at treating methylmalonic acidemia in early 2021. The licensing of its SEL-212 product candidate for chronic refractory gout to Sobi further highlights Selecta's strategic advancements.

Positive

• Plans to enter clinical trials for AAV gene therapies aimed at treating methylmalonic acidemia in early 2021.
• Licensing of SEL-212 for chronic refractory gout to Sobi enhances product pipeline.

Negative

• None.

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, March 11, 2020, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10147796. Investors and the public can access the live and archived webcast of this call via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

FAQ

When is Selecta Biosciences' conference call for Q4 and full-year 2020 results?

Selecta Biosciences will host the conference call on March 11, 2020, at 8:30 a.m. ET.

What is the purpose of Selecta Biosciences' upcoming conference call?

The conference call will discuss the financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.

What is the significance of ImmTOR™ platform for Selecta Biosciences?

The ImmTOR™ platform is used to develop tolerogenic therapies that mitigate unwanted immune responses, potentially enhancing biologic therapy efficacy.

What recent development has Selecta Biosciences made in gene therapy?

Selecta Biosciences plans to initiate clinical trials in early 2021 for its gene therapies targeting methylmalonic acidemia.